IACS-010759, an oxidative phosphorylation inhibitor, was evaluated in a Phase 1 trial for relapsed or refractory acute myeloid leukemia (AML). The trial was sponsored by M.D. Anderson Cancer Center and aimed to establish the maximum tolerated dose and assess safety and efficacy. However, the study was terminated due to a lack of effectiveness, indicating potential challenges in market viability. The competitive landscape for AML treatments remains robust, with multiple therapies available, necessitating a thorough diligence review for any future development or licensing opportunities.